Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Novartis Hedges Its Bet On Fingolimod In MS

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Submission of backup compound would come three years after filing of initial candidate.

You may also be interested in...



Good News, Bad News For Novartis' Oral MS Drug, But REMS Could Help

Novartis' fingolimod, which could become the first oral treatment for relapsing-remitting multiple sclerosis, recently beat Biogen Idec's Avonex in a head-to-head Phase III trial. The bad news for Novartis is that a handful of severe safety signals, spotted in Phase II, recurred in this most recent trial of the drug

Good News, Bad News For Novartis' Oral MS Drug, But REMS Could Help

Novartis' fingolimod, which could become the first oral treatment for relapsing-remitting multiple sclerosis, recently beat Biogen Idec's Avonex in a head-to-head Phase III trial. The bad news for Novartis is that a handful of severe safety signals, spotted in Phase II, recurred in this most recent trial of the drug

Good News, Bad News For Novartis’ Oral MS Drug, But REMS Could Help

Tysabri’s REMS could prove to be a model for drugs with serious safety signals.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Two Targeted Oncologics And A Novel SGLT-2 Inhibitor Clear US FDA

US Medicare Price Negotiation: Gaming FDA Approval Dates Could Delay Drug Selection

Rezafungin Review Highlights US FDA’s ‘Flexible Development' Approach For Antimicrobials

FDA Urged To Collaborate With USPTO On Orange Book Listings, Eliminate Patent Use Codes

See All
UsernamePublicRestriction

Register

PS067101

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By